CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
LowReport
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "strong-buy" rating re-affirmed by analysts at WBB Securities. They now have a $40.00 price target on the stock.
LowReport
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "strong-buy" rating re-affirmed by analysts at WBB Securities. They now have a $40.00 price target on the stock.
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its price target raised by analysts at Needham & Company LLC from $3.00 to $25.00. They now have a "buy" rating on the stock.
LowReport
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its price target raised by analysts at Needham & Company LLC from $3.00 to $25.00. They now have a "buy" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: